Leap Therapeutics Reports Second Quarter 2020 Financial Results

On August 13, 2020 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the second quarter ended June 30, 2020 (Press release, Leap Therapeutics, AUG 13, 2020, sec.gov/Archives/edgar/data/1509745/000110465920094315/tm2027468d1_ex99-1.htm [SID1234563574]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leap Second Quarter Highlights:

Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
Presented updated data for DKN-01 monotherapy that showed a complete response and partial response in endometrial cancer patients with additional responses observed for the DKN-01 plus paclitaxel combination in carcinosarcoma patients
Announced Orphan Drug Designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer
"Our partnership with BeiGene for the clinical development and commercialization of DKN-01 is progressing extremely well, and we look forward to dosing the first patient this quarter in the combination study of DKN-01 plus tislelizumab, BeiGene’s anti-PD-1 antibody, for the treatment of gastric or gastroesophageal junction cancer patients," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "DKN-01 continues to show potential to treat multiple biomarker-defined cancers, as both a single agent and in combination with chemotherapy or anti-PD-1 therapies. We are excited about the promise of this program and, with the proceeds from our recent public offering, are well funded to drive development forward."

Business Update

Leap Completed $51.75 Million Public Offering of Common Stock and Pre-Funded Warrants to Purchase Common Stock – In June 2020, Leap announced the closing of an underwritten public offering yielding aggregate gross proceeds of $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap.
DKN-01 Clinical Update

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. DKK1 has an important role in tumor cell signaling and in mediating an immuno-suppressive tumor microenvironment.

Leap Presented Updated Data for DKN-01 Monotherapy and Paclitaxel Combination in Gynecologic Cancers – Leap announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, as both a monotherapy and in combination with paclitaxel chemotherapy, in patients with advanced gynecological malignancies. Leap hosted a conference call with Rebecca Arend, M.D., Assistant Professor and Associate Scientist, Gynecologic Oncology Clinic, The University of Alabama at Birmingham School of Medicine Comprehensive Cancer Center Experimental Therapeutics Program, on April 23, 2020, to discuss the data. Key findings from the P204 study include the following:
DKN-01 Monotherapy in Endometrial Cancer: Twenty-nine endometrial cancer patients were enrolled in the DKN-01 monotherapy arm, over 75% of whom had experienced three or more prior lines of therapy. Of those patients, 26 were evaluable for response. In the 20 patients with a Wnt signaling alteration, one patient (5%) has an ongoing complete response, one patient (5%) had a partial response, eight patients (40%) had a best response of stable disease, and 10 patients (50%) had progressive disease, representing an overall response rate (ORR) of 10% and a disease control rate (DCR) of 50%. In the group of six patients without any Wnt signaling alterations, one patient (16.6%) had a best response of stable disease and five patients (83.3%) had progressive disease.
DKN-01 plus Paclitaxel in Carcinosarcoma: Fifteen patients with carcinosarcoma were enrolled in the DKN-01 plus paclitaxel arm, six of whom were evaluable for response as of the data-cutoff date. Two patients (33%) have had a partial response, one patient (17%) has had a best response of stable disease, and three patients (50%) had progressive disease, representing an ORR of 33% and a DCR of 50%. Nine patients had not reached their first tumor assessment.
Leap Announced Orphan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer – Leap announced that the U.S. Food and Drug Administration (FDA) granted the Company Orphan Drug Designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. The FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides to Leap certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees, and tax credits for qualified clinical trials.
Selected Second Quarter 2020 Financial Results

Net loss was $6.5 million for the second quarter 2020, compared to $8.4 million for the same period in 2019. This decrease was primarily due to revenue recognized from the BeiGene agreement, a decrease in clinical development expenses and non-cash foreign currency gains associated with changes in the Australian dollar exchange rate related to certain manufacturing activities.

Research and development expenses were $5.4 million for the second quarter 2020, compared to $6.1 million for the same period in 2019. The decrease was primarily due to lower clinical trial costs due to timing of patient enrollment and lower consulting fees associated with research and development activities.

General and administrative expenses were $2.5 million for the second quarter 2020, compared to $2.3 million for the same period in 2019. The increase was primarily due to higher legal, audit and consulting fees associated with corporate and business development activities.

Cash, cash equivalents and marketable securities totaled $64.9 million at June 30, 2020. Research and development incentive receivables, current and long term, totaled approximately $0.3 million at June 30, 2020.

Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results

On August 13, 2020 Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported its financial results for the second quarter and year-to-date for the period ended June 30, 2020 (Press release, Navidea Biopharmaceuticals, AUG 13, 2020, View Source [SID1234563601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The past four months have been truly momentous for the company. The successful second interim look showed how valuable our diagnostic agent will be for the effective management of Rheumatoid Arthritis," said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. "The signing of the binding MOU with Jubilant is a transformational event for the future of Navidea. Partnering with the second largest radiopharmaceutical company in the United States and a global leader in pharmaceuticals is something we have worked hard to achieve for many years. Furthermore, the $25 million in growth capital pledged by a top-notch syndicate of investors has assured the company’s non-RA related growth funding for years to come."

Second Quarter 2020 Highlights and Subsequent Events

Executed a binding memorandum of understanding ("MOU") on August 9, 2020 with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division ("Jubilant"). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement for Navidea’s Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant made a $1 million equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed.
Signed a binding commitment letter on August 9, 2020 with Mastiff Group LLC, for a private placement financing of up to $25 million in aggregate gross proceeds of shares of Navidea’s common stock, to be priced either "at the market" or at a premium to Navidea’s closing price on the date of execution. Navidea expects to sign definitive documents for a common stock only transaction, with an investor syndicate comprised of Mastiff Group LLC, John Kim Scott, Jr. and other fundamental biotech focused investors no later than August 18, 2020, with the closing to take place within 15 business days thereafter.
Regained the commercialization and distribution rights for Lymphoseek (Tc99m tilmanocept) injection in Europe through the mutually agreed upon termination of the perpetual license agreement with SpePharm AG, a subsidiary of Norgine B.V.
Finalized the previously announced $4.2 million financing related to the judgment by the Ohio Court of Common Pleas (the "Judgment"). Navidea agreed to issue Keystone Capital Partners, LLC, up to $4.2 million of convertible preferred shares, which will be guaranteed by a portion of the proceeds of the Judgment.
Announced positive preliminary results from the Company’s second interim analysis of its ongoing NAV3-31 Phase 2b study. Analysis demonstrated that these interim data further corroborate Navidea’s hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis ("RA"), and that this imaging can provide an early indicator of treatment efficacy in patients with active RA.
Achieved full enrollment in its ongoing NAV3-31 Phase 2b study titled "Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc99m Tilmanocept Planar Imaging." All of the subjects have been enrolled in the three-arm trial, with the protocol-specified longitudinal imaging events on track.
Presented results from the Company’s first interim analysis of its ongoing NAV3-31 phase 2b clinical study, titled, A Phase 2b Study of Intravenously Administered Tc 99m Tilmanocept to Determine Differential Uptake, Reproducibility Over Time and Image Stability in Healthy Subjects and in Patients with Rheumatoid Arthritis ("RA") on Stable Treatment, at the European League Against Rheumatism ("EULAR") Congress 2020.
Continued enrollment in the Investigator Initiated Phase 2 trial being run at the Massachusetts General Hospital evaluating Tc99m tilmanocept uptake in atherosclerotic plaques of HIV-infected individuals.
Filed a provisional patent on improved synthesis of Tilmanocept.
Received a one-year extension on its NIH phase 1 Small Business Technology Transfer grant (1R41HL147640-01A1) entitled Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques, due to COVID-19 related shutdown of the research facility at the University of Alabama Birmingham. The site has reopened and these preclinical studies are ongoing.
Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, "The clinical research team continues to work diligently to advance the technology in key disease areas, with an emphasis on our RA program. Our currently running Phase 2b trial in RA is proceeding well and, building upon the interim analysis results, we are preparing to discuss the upcoming Phase 3 with the FDA. We are also preparing for the start of our second Phase 2b trial comparing tilmanocept imaging to synovial tissue biopsy samples of RA patients."

Financial Results

Total revenues for the second quarter 2020 were $271,000, compared to $260,000 for the same period in 2019. Total revenues for the first half of 2020 were $427,000, compared to $302,000 for the same period in 2019. The increases were primarily due to increased grant revenue related to Small Business Innovation Research grants from the National Institutes of Health supporting Manocept development.
Research and development ("R&D") expenses for the second quarter of 2020 were $1.3 million, compared to $1.1 million in the same period in 2019. R&D expenses for the first half of 2020 were $2.3 million, compared to $1.8 million in the same period in 2019. The increases were primarily due to net increases in drug project expenses, including increased Manocept diagnostic development costs offset by decreased Manocept therapeutic development costs, coupled with increased employee compensation.
Selling, general and administrative ("SG&A") expenses for the second quarter of 2020 were $1.3 million, compared to $1.9 million in the same period in 2019. SG&A expenses for the first half of 2020 were $3.2 million, compared to $3.6 million in the same period in 2019. The decrease was primarily due to decreased legal and professional services, travel, insurance, depreciation, and investor relations costs, offset by increased employee compensation and franchise taxes.
Navidea’s net loss attributable to common stockholders for the second quarter of 2020 was $2.4 million, or $0.11 per share, compared to $2.7 million, or $0.24 per share, for the same period in 2019. Navidea’s net loss attributable to common stockholders for the first half of 2020 was $5.1 million, or $0.24 per share, compared to $5.1 million, or $0.48 per share, for the same period in 2019.
Navidea ended the second quarter of 2020 with $1.6 million in cash and investments. Since June 30, 2020, the Company has received the final $3.9 million of cash related to the February 2020 funding transactions. In addition, the Company received $1.0 million related to execution of the Jubilant MOU in August 2020.
Conference Call Details

Investors and the public are invited to dial into the earnings call through the information listed below, or participate via the audio webcast on the company website. Participants who would like to ask questions during the question and answer session will be prompted by the moderator, who will provide instructions.

Event:

Q2 2020 Earnings and Business Update Conference Call

Date:

Thursday, August 13, 2020

Time:

5:00 p.m. (EDT)

U.S. & Canada Dial-in:

877-407-0312

International Dial-in:

+1 201-389-0899

Conference ID:

13708190

Webcast Link:

View Source

A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

On August 13, 2020 WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, reportedits reviewed financial results for the first half of 2020 (Reporting Period) (Press release, WuXi AppTec, AUG 13, 2020, View Source [SID1234563618]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This document serves purely as a summary and is not intended to provide a complete representation of the relevant matters. For further information, please refer to the 2020 first half report and relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of relevant information. Investors are advised to exercise caution and be aware of the investment risks in dealing in the shares of the Company.

All financials disclosed in this press release are prepared based on International Financial Reporting Standards (IFRS).

Second Quarter 2020 Financial Highlights

Revenue grew 29.4% YoY to RMB4,044 million. Our laboratories and manufacturing facilities in China resumed full operations and were met with an increased demand from overseas customers. Consequently, we achieved strong revenue growth in the second quarter, driven by robust demand, increase in capacity utilization and efficient operations.
– Our China-based laboratory services realized revenue of RMB2,060 million, representing a YoY growth of 31.5%.
– Our CDMO/CMO services realized revenue of RMB1,314 million, representing a YoY growth of 43.9%.
– Our U.S.-based laboratory services realized revenue of RMB394 million, representing a YoY growth of 0.7%.
– Our clinical research and other CRO services realized revenue of RMB271 million, representing a YoY growth of 7.4%.
IFRS gross profit grew 27.1% YoY to RMB1,562 million. Gross profit margin was 38.6%, lower than the 39.3% achieved in the same period last year[1], mainly because of: (1) the impact of COVID-19 on our U.S.-based laboratory services and clinical research services business, and (2) an increase in share-based compensation expenses.
Non-IFRS gross profit grew 31.6% YoY to RMB1,694 million. Non-IFRS gross profit margin was 41.6% compared to 40.9% for the same period in 2019 and increased significantly compared with First Quarter 2020, mainly because: (1) our China-based laboratory services and CDMO/CMO services segments resumed at full operating capacity and secured more projects from overseas customers, offsetting the impact of COVID-19 on our U.S.-based laboratory services and clinical research services; and (2) we continued to gain efficiency through increased capacity utilization and efficient operations.
EBITDA grew 79.6% YoY to RMB1,854 million.
Adjusted EBITDA grew 22.7% YoY to RMB1,415 million.
Net profit attributable to owners of the Company grew 111.0% YoY to RMB1,414 million. Fair value gain of our investment portfolio increased from RMB134 million in the second quarter of 2019 to RMB1,044 million in the same period this year.
Adjusted Non-IFRS net profit attributable to owners of the Company grew 43.1% YoY to RMB942 million. The growth rate significantly accelerated compared with that of First-Quarter 2020.
Diluted Non-IFRS EPS increased by 110.3% versus the same period last year and adjusted diluted Non-IFRS EPS increased by 46.4%.[2]
[1] If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 27.7% YoY to RMB1,570 million. Gross profit margin was 38.8%, lower than the 39.4% achieved in the same period last year.

[2] Three months ended June 30, 2019 and three months ended June 30, 2020, we had a fully-diluted weighted average share count of 2,284 million and 2,302 million ordinary shares, respectively.

First Half of 2020 Financial Highlights

Revenue grew 22.7% YoY to RMB7,231 million, attributable to the timely implementation of our Business Continuity Plan, as well as the strong growth of our China-based laboratory services and CDMO/CMO services in response to the increased demand from our overseas customers.
– Our China-based laboratory services realized revenue of RMB3,780 million, representing a YoY growth of 26.5%.
– Our CDMO/CMO services realized revenue of RMB2,162 million, representing a YoY growth of 25.8%.
– Our U.S.-based laboratory services realized revenue of RMB782 million, representing a YoY growth of 10.1%.
– Our clinical research and other CRO services realized revenue of RMB500 million, representing a YoY growth of 5.9%.
IFRS gross profit grew 16.4% YoY to RMB2,659 million. Gross profit margin was 36.8%, lower than the 38.7% achieved in the same period last year[3], mainly because of: (1) the impact of COVID-19 on our China-based laboratory services (Q1), U.S.-based laboratory services (Q2) and clinical research services (Q1 & Q2) business; and (2) an increase in share-based compensation expenses.
Non-IFRS gross profit grew 21.7% YoY to RMB2,918 million. Non-IFRS gross profit margin was 40.1%, compared to 40.4% during the same period in 2019. We implemented our Business Continuity Plan early on and were successful in mitigating the negative impact of COVID-19 on our business. Our Non-IFRS gross profit margin was largely in line with that of the First Half 2019.
EBITDA grew 47.9% YoY to RMB2,600 million.
Adjusted EBITDA grew 20.7% YoY to RMB2,450 million.
Net profit attributable to owners of the Company grew 62.5% YoY to RMB1,717 million. Fair value gain of our investment portfolio increased from RMB55 million loss in the first half of 2019 to RMB939 million gain in the same period this year.
Adjusted Non-IFRS net profit attributable to owners of the Company grew 28.9% YoY to RMB1,519 million.
Diluted IFRS EPS increased by 60.9% versus the same period last year and adjusted diluted Non-IFRS EPS increased by 29.4%.[4]
[3] If prepared under Accounting Standard for Business Enterprises of PRC, the gross profit grew 16.7% YoY to RMB2,668 million. Gross profit margin was 36.9%, lower than the 38.8% achieved in the same period last year.

[4] Six months ended June 30, 2019 and six months ended June 30, 2020, we had a fully-diluted weighted average share count of 2,284 million and 2,301 million ordinary shares, respectively.

First Half 2020 Business Highlights

During the reporting period, we added about 600 new customers, increasing our active customer count to more than 4,000. Our "long-tail" strategy and "Follow the Customer/Follow the Project/Follow the Molecule" business model continued to perform very well.
– Our global platform continued to enable innovation worldwide. During the reporting period, our overseas customers contributed RMB5,546 million revenue, representing a YoY growth of 22.3%. Our China customers contributed RMB1,686 million revenue, representing a YoY growth of 23.9%.
– We continued to expand our customer base and retain existing customers. During the reporting period, our existing customers contributed RMB6,831 million revenue, representing a YoY growth of 22.5%. Our newly added customers contributed RMB401 million revenue, representing a YoY growth of 26.7%.
– We continued to execute our "long-tail" strategy and increased our support to large global pharmaceutical companies. During the reporting period, our global "long-tail" customers and China-based customers contributed RMB4,926 million revenue, representing a YoY growth of 28.7%. The top 20 global pharmaceutical companies contributed RMB2,305 million revenue, representing a YoY growth of 11.6%.
-We continued to increase customer conversion and enhance synergies across our platform. During the reporting period, customers using services from more than one of our business units contributed RMB6,151 million revenue, representing a YoY growth of 31.8%.
In small molecule drug discovery services, leveraging our large-scale and experienced global small molecule chemical drug research and development teams, we continued to assist global customers in discovering pre-clinical drug candidates and patent applications, with multiple research papers published in leading scientific journals.
We anticipated the industry trend early on and empowered our global customers with cutting-edge technology. To highlight a few examples, we offered:
– New mechanism of actions (MOA): our PROTAC platform maintained strong momentum, enabling over 40 biotech customers and resulting in revenue growth of over 23%.
– New modalities: we further strengthened our oligonucleotide and peptide drug discovery and development capabilities in our China-based laboratory services, providing services to over 1,000 oligonucleotide and peptide projects, including library synthesis, custom synthesis, modification, route development, and kg scale non-GMP manufacturing.
With the comprehensive integration of our DNA-encoded library (DEL), protein production and structure-based drug design capabilities, our Target-to-Hit platform enabled over 300 customers globally, creating incremental business opportunities for our downstream business units.
In our success-based drug discovery service unit, we submitted IND filings for 13 new chemical entities (NCE) for our customers and obtained 9 CTAs. As of June 30, 2020, we have cumulatively submitted 98 NCE IND filings with the National Medical Products Administration (NMPA) for our customers and obtained 66 CTAs. As of June 30, 2020, there is 1 project in Phase III clinical trial, 8 projects in Phase II clinical trials, and 54 projects in Phase I clinical trials.
Our safety assessment services achieved very strong growth due to a surge in customer demand and increased capacity.
We leveraged our platform to prepare and facilitate submissions of our customers’ IND packages through our WuXi IND (WIND) service. During the reporting period, we signed 50 integrated WIND packages with our customers, helping many of our global and China-based customers submit their IND packages and obtain clinical trial approval from the U.S. Food and Drug Administration (FDA) under the Electronic Common Technical Document (eCTD) format.
We added over 260 new molecules into our small molecule CDMO/CMO services pipeline. In addition, our "Follow the Molecule" strategy resulted in 5 new commercial projects. We provided CDMO services to over 1,100 active projects, including 42 projects in Phase III clinical trials, and we provided commercial manufacturing services for 26 approved drugs. In serving China-based customers, we have 26 Marketing Authorization Holder (MAH) projects in progress, including 4 commercial projects.
Our cell and gene therapies CDMO services enabled customers globally. During the reporting period:
– Our laboratories and facilities in the U.S. provided services for 31 clinical stage projects, including 22 projects in Phase I clinical trials and 9 projects in Phase II/III clinical trials. In July 2020, we signed a late-phase manufacturing contract with a customer for its allogeneic cell therapy product, which is currently undergoing FDA priority review. As more of our customers enter late stage development in 2021, we expect our capacity utilization rate to further increase.
– Our laboratories and facilities in China added more customers and projects. In addition, we entered into a long-term partnership with our first customer for a commercial manufacturing project.
Our clinical research services continued to enable customers in China and the U.S. During the reporting period:
– Our clinical development team provided services to more than 130 projects for our clients in China and the U.S. and completed the registration trials for 5 products.
Our site management organization (SMO) team assisted in the market approval of 12 products for our customers, including the approval of a surgical implant for the treatment of glaucoma based on real world evidence in China.
First Half 2020 capabilities enhancement and capacities expansion:
– In January 2020, we started construction of a new drug product development and production facility at our CDMO subsidiary STA’s Wuxi site. This facility will not only improve the development and production capacity of solid dosages, but will also be capable of sterile drug product development, clinical trial material production and commercial scale manufacturing.
– Our high-potency active pharmaceutical ingredient (API) manufacturing facility, large-scale oligonucleotide API manufacturing facility and large-scale peptide API manufacturing facility in Changzhou, China began operations, supporting the process R&D and manufacture of small molecules, as well as oligonucleotide and peptide APIs from preclinical to commercial.
– Our Philadelphia cell and gene therapies facility expanded its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform and a fully integrated Closed Process CAR-T Cell Therapy Platform, which will help our customers accelerate the timeline for cell and gene therapy development, manufacturing and release.
– Our Wuxi City cell therapy CDMO facility began operations, providing services to multiple customers. We launched our AAV adherent manufacturing platform and started to build an AAV Vector Suspension Platform in China.
– In July 2020, our newly-built Chengdu research and development center began operations.
Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We achieved strong growth in the first half of 2020, in spite of the impact of COVID-19 on our China-based laboratory services in the first quarter, U.S.-based laboratory services in the second quarter, and clinical research services. Our revenue grew 22.7% year-over-year to RMB7,231 million and our adjusted Non-IFRS net profit grew 28.9% year-over-year to RMB1,519 million. Strong performance from our China-based laboratory services and CDMO/CMO services mitigated any challenges faced by our U.S.-based laboratory services and clinical research services."

"Our global enabling platform and ‘Follow the Customer/Follow the Project/Follow the Molecule’ strategy continued to perform very well. China-based laboratory services and CDMO/CMO services resumed full operations and achieved robust growth, attributable to increased business opportunities and improved utilization and efficiency. Our U.S.-based laboratory services, clinical research and other CRO services segments, although severely impacted by COVID-19, still realized revenue growth and our backlog continued to improve quarter-over-quarter. In regard to the Company’s financial position, in August 2020 we completed the placing of new H shares, receiving approximately HK$7.29 billion in net proceeds, providing the Company with a strong balance sheet for investments, business expansion and potential M&A."

Dr. Ge Li concluded, "2020 has been a year full of challenges and opportunities. We achieved solid growth in the first half of 2020 as a result of the combined efforts of all our employees and support from our customers globally. We are determined to navigate through the challenges posed by COVID-19 in partnership with our global customers, and are committed to working alongside our customers and partners in the global healthcare community to keep the R&D and manufacturing engine humming. The fundamentals of our business remain very strong and we expect to deliver a strong second half. Looking ahead, we will continue to focus on enabling our global partners and doing the right thing for patients in order to realize our vision that ‘every drug can be made and every disease can be treated.’"

Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates

On August 13, 2020 Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, reported financial results for the six months ended June 30, 2020 and corporate updates (Press release, Zai Laboratory, AUG 13, 2020, View Source [SID1234563575]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year we have continued to build Zai Lab’s leadership through strong execution. Highlights include two successful commercial launches in China, NMPA approval for Optune, two highly strategic collaboration deals, three NDAs accepted with priority review, 15 clinical trial authorizations approved and eight trial initiations across our innovative pipeline which now includes 14 clinical stage assets," said Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab. "We were able to overcome headwinds brought on by the COVID-19 pandemic, launching both ZEJULA and Optune in under six weeks from regulatory approval and gaining immediate support from the medical, patient and payor communities. Our clinical pipeline continues to strengthen with the addition of two key late-stage assets, REGN1979 and Repotrectinib. With our broad and differentiated pipeline, we remain confident that Zai Lab can become a leading global biopharma company, leveraging our capabilities and network to drive the next wave of innovations with transformative impact on patients with significant unmet medical needs. Over the next three years, we expect to have a steady stream of approvals and commercial product launches in Greater China across multiple therapeutic areas, establish transformative partnerships, expand our global footprint, and advance our internally discovered global pipeline into the pivotal stage."

Key Product Highlights and Near Term Milestones

Oncology

ZEJULA (Niraparib)

ZEJULA is an oral, once-daily small molecule poly (ADP-ribose) PARP 1/2 inhibitor. It is the only once-daily PARP inhibitor approved in the US as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings.

In May 2020, Zai Lab announced positive topline results from the NORA Phase 3 study of ZEJULA as maintenance therapy for Chinese patients with platinum-sensitive, recurrent ovarian cancer.

In April 2020, the China National Medical Products Administration (NMPA) granted priority review to the supplemental New Drug Application (sNDA) for ZEJULA (niraparib) for first-line ovarian cancer maintenance treatment.

Since the commercial launch in January 2020 in China, ZEJULA has been included for regional reimbursement in one province and six cities. It has also been listed in 16 commercial health insurances and four supplemental insurance initiated by provincial or municipal governments.
Near-term Milestones

Detailed presentation at an upcoming global medical conference of the NORA Phase 3 study of ZEJULA as maintenance therapy for Chinese patients with platinum-sensitive, recurrent ovarian cancer expected in second half of 2020.

Initiate registrational bridging trial for late-line ovarian cancer treatment in second half of 2020.

Collaborate with our partner GSK to study additional indications and combinations for niraparib.
Tumor Treating Fields

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cell death.

In August 2020, Optune LuaTM launched for the treatment of malignant pleural mesothelioma (MPM) in Hong Kong.

In May 2020, the China NMPA approved Optune for the treatment of newly diagnosed and recurrent glioblastoma.
Near-term Milestones

Join global Phase 3 pivotal trials in non-small cell lung cancer, locally advanced pancreatic cancer and brain metastases in mainland China. Hong Kong, Macau and Taiwan by early 2021.

File Marketing Authorization Application (MAA) for MPM in China in first half of 2021.

Announce clinical data readout of the Phase 2 pilot trial in first-line gastric adenocarcinoma in 2021.

Partner milestones:
Interim analysis of Phase 3 pivotal LUNAR trial in non-small cell lung cancer expected in 2021.
Interim analysis of Phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer expected in 2021.
Interim analysis of Phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer expected in 2021.
Data from Phase 2 pilot HEPANOVA trial in advanced liver cancer expected in 2021.
Ripretinib

Ripretinib is a KIT and PDGFRα kinase switch control inhibitor for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors (GIST), systemic mastocytosis, and other cancers. It is the only therapeutic approved in the US for advanced GIST patients who have received three or more lines of treatment in the all-comer setting.

In August 2020, the China NMPA granted Priority Review to the New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced GIST.

In July 2020, the China NMPA accepted the NDA submission of ripretinib for advanced GIST.

In July 2020, Zai Lab received the Clinical Trial Authorization (CTA) approval for the registrational bridging study of ripretinib in patients with second-line GIST.
Near-term Milestones

Initiate the bridging trial for second-line GIST in second half of 2020.
Odronextamab (REGN1979)

Odronextamab is an investigational bispecific monoclonal antibody that is designed to trigger tumor killing by linking and activating a cytotoxic T-cell (binding to CD3) to a lymphoma cell (binding to CD20).

In April 2020, Zai Lab announced a strategic collaboration with Regeneron for the development and exclusive commercialization of odronextamab in oncology in mainland China, Hong Kong, Taiwan and Macau.
Near-term Milestones

Enroll first Chinese patient into the potentially registrational global Phase 2 program by early 2021.
Repotrectinib

Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and TRK A/B/C with potential to treat TKI-naïve or TKI-pretreated patients.

In July 2020, Zai Lab announced an exclusive license agreement with Turning Point Therapeutics for the development and commercialization of repotrectinib in mainland China, Hong Kong, Taiwan and Macau.
Near-term Milestones

Enroll first Chinese patient into the global TRIDENT-1 Phase 2 study by early 2021.

Partner milestone: Early interim data from initial patients in the TRIDENT-1 Phase 2 study in third quarter of 2020.
Margetuximab

Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2).

Near-term Milestones

Enroll first Chinese patient into the global Phase 2/3 MAHOGANY study as a front-line treatment for advanced gastric and gastroesophageal junction cancer in second half of 2020.

Partner milestone: The Prescription Drug User Fee Act (PDUFA) target action date for the Biologics License Application (BLA) for margetuximab in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer is December 18, 2020.
Infectious Disease

NUZYRA (Omadacycline)

NUZYRA is a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

In May 2020, the China NMPA granted priority review to the NDA for omadacycline for the treatment of CABP and ABSSSI.
Durlobactam

Durlobactam is a beta-lactamase inhibitor which, in combination with sulbactam, provides unique activity against Acinetobacter organisms, including carbapenem-resistant strains (CRAB).

In May 2020, the first Chinese patient was enrolled into the global Phase 3 ATTACK trial of Sulbactam-Durlobactam (SUL-DUR) for Acinetobacter infections.
Internal Programs with Global Rights

ZL-1201

ZL-1201 is a humanized, IgG4 monoclonal antibody engineered to reduce effector function, that specifically targets CD47. Its therapeutic potential will be assessed in both solid tumors and hematological malignancies, in both mono and combination opportunities.

In June 2020, first-in-human dosing was achieved in the Phase 1 study.
ZL-1102

ZL-1102 is a novel human nanobody targeting IL-17 with high affinity and avidity. Unlike other anti-IL-17 products, ZL-1102 is being developed as a topical treatment for chronic plaque psoriasis (CPP).

In July 2020, first-in-human dosing was achieved in the Phase 1 study.
Other Upcoming Milestones

Tebotelimab (MGD013) – a first-in-class, bispecific PD-1 x LAG-3 DART molecule.

Enroll first Chinese patient into the global Phase 1 basket trial in second half of 2020.

Zai Lab’s partner MacroGenics is expanding enrollment of the combination of tebotelimab and margetuximab in a cohort of patients with advanced HER2-positive tumors.
Retifanlimab – an anti-PD-1 monoclonal antibody.

Initiate potentially registration-enabling study in second-line MSI-high endometrial cancer in China in second half of 2020.

Enroll first Chinese patient into the Incyte-sponsored global Phase 3 study of retifanlimab with platinum-based chemotherapy in first-line metastatic squamous and non-squamous non–small cell lung cancer in second half of 2020.
Bemarituzumab – a first-in-class antibody for tumors that overexpress FGFR2b.

Zai Lab’s partner Five Prime Therapeutics expects the topline results of the Phase 2 FIGHT study by the end of 2020 or in early 2021.
Business Development

Continue to pursue bolt-on and transformational business development opportunities.
Corporate Update

Zai Lab continues to expand its US presence to enhance internal drug discovery, clinical development and business development, with the opening of a 20,000 sq. ft new research facility in Menlo Park, CA and the expansion of our office in Boston, MA.

Zai Lab continues to expand and hire talented professionals. As of June 2020, Zai Lab employed 859 full-time employees, with 366 and 377 employees engaged in R&D and commercial activities, respectively.

Zai Lab appointed several executives with extensive experience in R&D, regulatory affairs and alliance management including Dr. Karl Hsu, Senior Vice President (SVP) of Clinical Research and Early Development; Angela Jiang, SVP of Regulatory Affairs; and Petter Veiby, Head of Alliance Management and Business Development Search & Evaluation. Valeria Fantin, Chief Scientific Officer, will leave Zai Lab by September 25, 2020 to pursue a new opportunity.
First-Half 2020 Financial Results

For the six months ended June 30, 2020, net product revenues were $19.2 million, compared to $3.4 million for the same period in 2019. Revenues for the period were comprised of $13.8 million in sales of ZEJULA and $5.4 million in sales of Optune, respectively. Launched in January 2020, ZEJULA’s revenue in mainland China was the main driver for the first half of 2020 given Optune was commercially available at the end of June.

R&D expenses were $102.0 million for the six months ended June 30, 2020, compared to $58.9 million for the same period in 2019. The increase in R&D expenses were primarily attributable to increased fees in connection with the upfront and milestone payments for new licensing and strategic collaboration agreements, ongoing and newly initiated late-stage clinical trials, payroll and payroll-related expenses from increased R&D headcount and expansion of research efforts to support internal development programs.

Selling, General & Administrative expenses were $42.5 million for the six months ended June 30, 2020 compared to $29.5 million for the same period in 2019. The increase was primarily due to payroll and payroll-related expenses from increased commercial headcount and related costs as Zai Lab expanded its commercial operations in China.

For the six months ended June 30, 2020, Zai Lab reported a net loss of $128.6 million, or a net loss per share attributable to common stockholders of $1.74, compared to a net loss of $83.3 million, or net loss per share attributable to common stockholders of $1.37, for the same period in 2019.

As of June 30, 2020, cash and cash equivalents, restricted cash and short-term investments totaled $464.1 million.
Conference Call and Webcast Information

Zai Lab will host a live conference call and webcast today, August 13, 2020 at 8:00 a.m. ET. Listeners may access the live webcast by visiting the Company’s website at View Source Participants must register in advance of the conference call. Details are as follows:

Registration Link: View Source

Conference ID: 7077004
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website at View Source

Entry into a Material Definitive Agreement

On August 13, 2020, Aclaris Therapeutics, Inc., a Delaware corporation referred to herein as we, us, our or the Company, reported that it entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we may sell to Lincoln Park up to $15,000,000 of shares of our common stock, or the Purchase Shares, from time to time over the 36-month term of the Purchase Agreement (Filing, 8-K, Aclaris Therapeutics, AUG 13, 2020, View Source [SID1234563602]). Concurrently with entering into the Purchase Agreement, we also entered into a registration rights agreement with Lincoln Park, or the Registration Rights Agreement, pursuant to which we agreed to register the sale of the shares of our common stock that may be issued to Lincoln Park under the Purchase Agreement pursuant to our existing shelf registration statement on Form S-3 or a new registration statement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After the Commencement Date (as defined below), on any business day selected by us, if the closing sale price of our common stock on the Nasdaq Global Select Market, or Nasdaq, is not below $0.25, we may direct Lincoln Park to purchase up to 100,000 shares of our common stock on such business day (or the purchase date), which we refer to as a Regular Purchase, provided, however, that (i) a Regular Purchase may be increased to up to 125,000 shares if the closing sale price of our common stock on Nasdaq is not below $1.50 on the applicable purchase date, (ii) a Regular Purchase may be increased to up to 200,000 shares if the closing sale price of our common stock on Nasdaq is not below $2.50 on the applicable purchase date and (iii) a Regular Purchase may be increased to up to 250,000 shares, if the closing sale price of our common stock on Nasdaq is not below $3.00 on the applicable purchase date. In each case, upon the parties’ mutual agreement, the maximum amount of any single Regular Purchase may be increased up to $2,000,000 of shares. We may direct Lincoln Park to purchase shares in Regular Purchases as often as every business day. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement.

The purchase price per share for each such Regular Purchase will be equal to the lesser of:

·the lowest sale price for our common stock on Nasdaq on the purchase date of such shares; and

·the average of the three lowest closing sale prices for our common stock on Nasdaq during the 10 consecutive business days prior to the purchase date of such shares.

In addition, we may also direct Lincoln Park, on any business day on which we have submitted a Regular Purchase notice for the maximum amount allowed for such Regular Purchase and the closing sale price of our common stock on Nasdaq is not below $0.50, to purchase an additional amount of our common stock, which we refer to as an Accelerated Purchase, of up to the lesser of:

·three times the number of shares purchased pursuant to such Regular Purchase; and

·30% of the aggregate shares of our common stock traded on Nasdaq during all or, if certain trading volume or market price thresholds specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase date, the portion of the normal trading hours on the applicable Accelerated Purchase date prior to such time that any one of such thresholds is crossed, which period of time on the applicable Accelerated Purchase date we refer to as the Accelerated Purchase Measurement Period.

The purchase price per share for each such Accelerated Purchase will be equal to 97% of the lower of:

·the volume-weighted average price of our common stock on Nasdaq during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date; and

·the closing sale price of our common stock on Nasdaq on the applicable Accelerated Purchase date.

We may also direct Lincoln Park on any business day on which an Accelerated Purchase has been completed and all of the shares to be purchased thereunder have been delivered to Lincoln Park in accordance with the Purchase Agreement, provided that the closing price of our common stock on the business day immediately preceding such business day is not below $0.50, to purchase an additional amount of our common stock, which we refer to as an Additional Accelerated Purchase, of up to the lesser of:

·three times the number of shares purchased pursuant to the applicable corresponding Regular Purchase; and

·30% of the aggregate shares of our common stock traded on Nasdaq during a certain portion of the normal trading hours on the applicable Additional Accelerated Purchase date as determined in accordance with the Purchase Agreement, which period of time on the applicable Additional Accelerated Purchase date we refer to as the Additional Accelerated Purchase Measurement Period.

We may, in our sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park on a single Accelerated Purchase date, provided that all prior Accelerated Purchases and Additional Accelerated Purchases (including those that have occurred earlier on the same day) have been completed and all of the shares to be purchased thereunder have been properly delivered to Lincoln Park in accordance with the Purchase Agreement.

The purchase price per share for each such Additional Accelerated Purchase will be equal to 97% of the lower of:

·the volume-weighted average price of our common stock on Nasdaq during the applicable Additional Accelerated Purchase Measurement Period on the applicable Additional Accelerated Purchase date; and

·the closing sale price of our common stock on Nasdaq on the applicable Additional Accelerated Purchase date.

In the case of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase price.

Under applicable rules of Nasdaq, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock, including the Commitment Shares described below, in excess of 8,544,555 shares, which is equal to 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement, or the Exchange Cap, unless (i) we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.1912 per share (which represents the average of the official closing prices of our common stock on Nasdaq for the five trading days immediately preceding the signing of the Purchase Agreement), such that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules. In any event, the Purchase Agreement specifically provides that we may not issue or sell any shares of our common stock under the Purchase Agreement if such issuance or sale would breach any applicable rules or regulations of Nasdaq.

The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the Purchase Agreement may commence only after certain conditions have been satisfied, the date on which all requisite conditions have been satisfied is referred to herein as the Commencement Date, which conditions include the delivery to Lincoln Park of a prospectus supplement covering the shares of our common stock issued or sold by us to Lincoln Park under the Purchase Agreement, approval for listing on Nasdaq Global Select Market of the shares of our common stock issued or sold by us to Lincoln Park under the Purchase Agreement, the issuance of 121,584 shares of our common stock to Lincoln Park as Commitment Shares under the Purchase Agreement, and the receipt by Lincoln Park of a customary opinion of counsel and other certificates and closing documents. The Purchase Agreement may be terminated by us at any time, at our sole discretion, without any cost or penalty. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our common stock. There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings (other than restrictions on our ability to enter into additional "equity line" or similar transactions whereby an investor is irrevocably bound to purchase securities over a period of time from us at a price based on the market price of our common stock at the time of such purchase), rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. We may deliver Purchase Notices under the Purchase Agreement, subject to market conditions, and in light of our capital needs from time to time and under the limitations contained in the Purchase Agreement. Any proceeds that we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes.

The issuance of the Purchase Shares and Commitment Shares have been registered pursuant to our effective shelf registration statement on Form S-3 (File No. 333-237163), or the Registration Statement, and the related base prospectus included in the Registration Statement, as supplemented by a prospectus supplement filed on August 13, 2020, or the Prospectus Supplement. A copy of the legal opinion as to the legality of the shares of our common stock subject to the Purchase Agreement is filed as Exhibit 5.1 attached hereto.

The foregoing is a summary description of certain terms of the Purchase Agreement and the Registration Rights Agreement and, by its nature, is incomplete. Copies of the Purchase Agreement and the Registration Rights Agreement are filed as Exhibits 10.1 and 10.2 attached hereto. The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to such exhibits.

The Purchase Agreement and Registration Rights Agreement contain customary representations and warranties, covenants and indemnification provisions that the parties made to, and solely for the benefit of, each other in the context of all of the terms and conditions of such agreements and in the context of the specific relationship between the parties thereto. The provisions of the Purchase Agreement and Registration Rights Agreement, including any representations and warranties contained therein, are not for the benefit of any party other than the parties thereto and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the parties thereto. Rather, investors and the public should look to other disclosures contained in our annual, quarterly and current reports we may file with the Securities and Exchange Commission, or SEC.

The information contained in this Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of our common stock discussed herein, nor shall there be any offer, solicitation or sale of the shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.